Loading
Heart Failure With Preserved Ejection Fraction (HFPEF) / Weight loss SOC Treatment with second generation anti-diabetic medications · Observational Study
ClinicalTrials.gov · September 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered observational study of HFpEF patients undergoing medically directed weight loss, designed to examine mechanisms by which adiposity impairs exercise hemodynamics and microvascular function. No results are reported in this registry record; the study is currently enrolling by invitation with an estimated completion timeline of 9–12 months post-baseline.
Observational. Heart Failure With Preserved Ejection Fraction (HFPEF); age from 18 Years; accepts healthy volunteers. Intervention: HFpEF and Obesity Group; Control Group (Non-HFpEF and Obesity). n = 95. 1 site: United States.
This is a registered observational study of HFpEF patients undergoing medically directed weight loss, designed to examine mechanisms by which adiposity impairs exercise hemodynamics and microvascular function. No results are reported in this registry record; the study is currently enrolling by invitation with an estimated completion timeline of 9–12 months post-baseline.
Primary endpoints are mechanistic and physiologic (perfusion, RNA expression) rather than clinical hard outcomes (mortality, hospitalization).
This mechanistic study will inform understanding of how adiposity and weight loss affect exercise tolerance and microvascular function in HFpEF if results confirm its hypotheses, but no clinical recommendations can be drawn until results are published and peer reviewed.
This is a registry record of an ongoing observational study with no results posted; it describes planned enrollment, design, and hypothesized mechanisms rather than reported outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This mechanistic study will inform understanding of how adiposity and weight loss affect exercise tolerance and microvascular function in HFpEF if results confirm its hypotheses, but no clinical recommendations can be drawn until results are published and peer reviewed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06930495). This is a study registration, not published results. Lead sponsor: University of Texas Southwestern Medical Center. Recruitment status: ENROLLING_BY_INVITATION. Study type: OBSERVATIONAL. Enrollment: 95 participants (ESTIMATED). Conditions: Heart Failure With Preserved Ejection Fraction (HFPEF). Interventions: DRUG: Weight loss SOC Treatment with second generation anti-diabetic medications. Primary outcome measures: Peak muscle perfusion during exercise , Pre intervention (Day 1); Peak muscle perfusion during exercise , Post intervention (Post Day 1); Single cell RNA sequencing of skeletal muscle , Pre intervention (Day 2); Single cell RNA sequencing of skeletal muscle , Post intervention (Day 2); Muscle to fat ratio of leg , Pre intervention (Day 3); Peak change in microvascular perfusion from rest to exercise , Pre intervention (Day 3); Muscle to fat ratio of leg , Post intervention (Day 3); Peak change in microvascular perfusion from rest to exercise , Post intervention (Day 3). Brief summary: This project is an observational study in patients with heart failure with preserved ejection fraction (HFpEF) who are candidates for treatment with weight loss medication to manage obesity or diabetes as part of their standard clinical care. This study will include multiple experimental visits before and after treatment (minimum 7 percent weight loss, between 9-12 months) to understand how increased adiposity and inflammation effects skeletal muscle and cardiovascular health and function and to examine the effect of medically directed weight loss on skeletal muscle health and exercise tolerance. The objective of this study is to 1. Define the mechanisms by which adiposity impairs exercise hemodynamics, microvascular function, and oxygen transport/utilization in patients with HFpEF. 2. Determine if intensive medically directed weight loss can reduce microvascular inflammation and normalize exercise hemodynamics. 3. Quantify the effect of medically directed weight loss on skeletal muscle function and catabolism. Hypotheses 1. Perfusion of subcutaneous adipose tissue disrupts blood flow distribution and impairs muscle microvascular perfusion and exercise hemodynamics. 2. Extramyocellular muscular lipid deposition and microvascular endothelial inflammation is associated with reduced capillarity and impaired microvascular perfusions, while intramyocellular triglyceride content is associated with poor skeletal muscle oxidative capacity, 3. Intensive weight loss will improve exercise hemodynamics, microvascular perfusion, and reduce muscular inflammation, and resistance training will augment these effects.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.